溴隐亭对中枢性发热的退热疗效:一项探索性分析
这项回顾性队列研究分析了2018年1月至2021年12月在一家三级医院神经重症监护室接受溴隐亭治疗的33例急性脑损伤伴疑似中枢性发热的成人患者(女性14例;平均年龄50岁,标准差14岁)。溴隐亭中位剂量为7.5 mg(范围2.5-40),中位疗程13天(范围5-160天)。采用广义相加混合模型分析显示,溴隐亭启动后体温显著下降(p < 0.05),24小时下降0.3°C、48小时下降0.5°C、72小时下降0.7°C。使用降温装置时体温降低0.2°C,同时使用退热药时降低0.1°C。作者认为溴隐亭使用与体温适度但统计学显著的下降相关,最低点出现在启动后72小时,为前瞻性评估提供了数据基础。
要点
- 在33例急性脑损伤伴疑似中枢性发热的成人中,溴隐亭启动后体温显著下降(p < 0.05):24小时-0.3°C、48小时-0.5°C、72小时-0.7°C。
- 溴隐亭中位剂量7.5 mg(范围2.5-40),中位疗程13天(范围5-160天)。
- 使用表面降温装置时预测体温降低0.2°C,同时使用退热药时降低0.1°C。
- 有创测温法预测体温较表面测温法高0.4°C(p < 0.05)。
- 年龄和性别未影响体温随时间的变化函数。
适用人群与场景
- 2018年1月至2021年12月在一家三级医院神经重症监护室接受溴隐亭治疗的成人急性脑损伤患者,疑似中枢性发热。
- 中枢性发热的判断通过临床记录回顾确定。
处置流程与药物剂量
- 溴隐亭中位剂量7.5 mg(范围2.5-40),中位疗程13天(范围5-160天)。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量33例(女性14例);平均年龄50岁,标准差14岁;单家三级医院神经重症监护室。
- 干预:溴隐亭,中位剂量7.5 mg(范围2.5-40),中位疗程13天(范围5-160天)。
- 主要终点:采用广义相加混合模型分析,溴隐亭启动后体温显著下降(p < 0.05),24小时-0.3°C、48小时-0.5°C、72小时-0.7°C,最低点在72小时。
- 协变量效应:有创测温法较表面测温法预测体温高0.4°C(p < 0.05);使用降温装置时体温降低0.2°C;同时使用退热药时降低0.1°C。
- 年龄和性别未影响体温随时间的变化函数。
证据类型、等级与局限
- 证据类型:回顾性队列研究(探索性分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,溴隐亭使用与急性脑损伤伴疑似中枢性发热成人患者体温适度但统计学显著的下降相关,最低点出现在启动后72小时,该发现为前瞻性评估提供了数据基础。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: 'Central' fevers are thought to result from disruption of hypothalamic thermoregulatory pathways following severe brain injuries. Bromocriptine, due to its central dopamine receptor agonism, has been hypothesized to have antipyretic effect in this setting. However, clinical evidence for this off-label use is limited to a few case reports. In this retrospective cohort study, we analyzed the effect of bromocriptine administration on body temperature in acute brain injury patients with suspected central fever.
METHODS: We screened a cohort of adult patients that received bromocriptine in the neurologic-intensive care unit of a tertiary care hospital between January 2018 and December 2021. Indication of central fever was ascertained by review of clinical documentation. A generalized additive mixed model (GAMM) was used to model temperature as a function of time relative to bromocriptine initiation. We adjusted for potential confounding due to the following covariates: temperature recording method (invasive vs surface), concurrent antipyretic administration within 8 h, and surface cooling device use within 4 h of temperature measurement. Temperature-time function was modeled using a cubic spline with k = 10 knots.
RESULTS: A total of 33 patients were included in the analysis (14 women; mean age: 50 y, standard deviation 14 y). Median dose of bromocriptine was 7.5 mg (range 2.5-40) for a median of 13 d (range 5-160). Age and sex did not impact the function of temperature over time. Predicted temperatures were significantly (p < 0.05) higher by 0.4 °C with invasive compared to surface recording methods, lower by 0.2 °C in the presence of cooling device use and lower by 0.1 °C with concurrent antipyretic use. On adjusted analysis with the GAMM, there was decline (p < 0.05) in temperature following bromocriptine initiation by - 0.3 °C at 24 h, - 0.5 °C at 48 h, and - 0.7 °C at 72 h.
CONCLUSIONS: Bromocriptine use was associated with modest but statistically significant decline in temperature, with nadir at 72 h post initiation. The findings provide a data driven basis for prospective evaluation.
参考来源
- Perez V, McCreary M, Sheperd L, et al. Antipyretic Efficacy of Bromocriptine in Central Fever: an Exploratory Analysis. Neurocrit Care. 2023. PMID: 36964441. doi:10.1007/s12028-023-01703-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。